United States - English - NLM (National Library of Medicine)

eon labs, inc. - sulfadiazine (unii: 0n7609k889) (sulfadiazine - unii:0n7609k889) - sulfadiazine tablets, usp are indicated in the following conditions: chancroid trachoma inclusion conjunctivitis nocardiosis urinary tract infections (primarily pyelonephritis, pyelitis and cystitis) in the absence of obstructive uropathy or foreign bodies, when these infections are caused by susceptible strains of the following organisms: escherichia coli , klebsiella species, enterobacter species, staphylococcus aureus , proteus mirabilis and p. vulgaris . sulfadiazine should be used for urinary tract infections only after use of more soluble sulfonamides has been unsuccessful. toxoplasmosis encephalitis in patients with and without acquired immunodeficiency syndrome, as adjunctive therapy with pyrimethamine. malaria due to chloroquine-resistant strains of plasmodium falciparum , when used as adjunctive therapy. prophylaxis of meningococcal meningitis when sulfonamide-sensitive group a strains are known to prevail in family groups or larger closed populations (the prophylactic usefulness of sulfonamides

United States - English - NLM (National Library of Medicine)

epic pharma, llc - sulfadiazine (unii: 0n7609k889) (sulfadiazine - unii:0n7609k889) - sulfadiazine tablets, usp are indicated in the following conditions: chancroid trachoma inclusion conjunctivitis nocardiosis urinary tract infections (primarily pyelonephritis, pyelitis and cystitis) in the absence of obstructive uropathy or foreign bodies, when these infections are caused by susceptible strains of the following organisms: escherichia coli, klebsiella species, enterobacter species, staphylococcus aureus, proteus mirabilis and p. vulgaris . sulfadiazine should be used for urinary tract infections only after use of more soluble sulfonamides has been unsuccessful. toxoplasmosis encephalitis in patients with and without acquired immunodeficiency syndrome, as adjunctive therapy with pyrimethamine. malaria due to chloroquine-resistant strains of plasmodium falciparum , when used as adjunctive therapy. prophylaxis of meningococcal meningitis when sulfonamide-sensitive group a strains are known to prevail in family groups or larger closed populations (the prophylactic usefulness of sulfonamides when group b or c infections are prevalent is not proved and may be harmful in closed population groups). meningococcal meningitis, when the organism has been demonstrated to be susceptible. acute otitis media due to haemophilus influenzae, when used concomitantly with adequate doses of penicilin. prophylaxis against recurrences of rheumatic fever, as an alternative to penicillin. h. influenzae meningitis, as adjunctive therapy with parental streptomycin. important notes in vitro sulfonamide susceptibility tests are not always reliable. the test must be carefully coordinated with bacteriologic and clinical response. when the patient is already taking sulfonamides, follow-up cultures should have aminobenzoic acid added to the culture media. currently, the increasing frequency of resistant organisms limits the usefulness of antibacterial agents, including the sulfonamides, especially in the treatment of recurrent and complicated urinary tract infections. wide variation in blood levels may result with identical doses. blood levels should be measured in patients receiving sulfonamides for serious infections. free sulfonamide blood levels of 5 mg to 15 mg per 100 ml may be considered therapeutically effective for most infections and blood levels of 12 mg to 15 mg per 100 ml may be considered optimal for serious infections. twenty mg per 100 ml should be the maximum total sulfonamide level, since adverse reactions occur more frequently above this level. sulfadiazine is contraindicated in the following circumstances: hypersensitivity to sulfonamides. in infants less than 2 months of age (except as adjunctive therapy with pyrimethamine in the treatment of congenital toxoplasmosis). in pregnancy at term and during the nursing period, because sulfonamides cross the placenta and are excreted in breast milk and may cause kernicterus.

United States - English - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - silver sulfadiazine (unii: w46jy43ejr) (sulfadiazine - unii:0n7609k889) - silver sulfadiazine 10 mg in 1 g - silver sulfadiazine cream, usp 1% is a topical antimicrobial drug indicated as an adjunct for the prevention and treatment of wound sepsis in patients with second and third degree burns. silver sulfadiazine cream, usp 1% is contraindicated in patients who are hypersensitive to silver sulfadiazine or any of the other ingredients in the preparation.      because sulfonamide therapy is known to increase the possibility of kernicterus, silver sulfadiazine cream, usp 1% should not be used on pregnant women approaching or at term, on premature infants, or on newborn infants during the first 2 months of life. geriatric use. of the total number of subjects in clinical studies of silver sulfadiazine cream, usp 1% seven percent were 65 years of age and over. no overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of s

United States - English - NLM (National Library of Medicine)

rebel distributors corp - silver sulfadiazine (unii: w46jy43ejr) (silver sulfadiazine - unii:w46jy43ejr) - silver sulfadiazine 10 mg in 1 g - thermazene® (silver sulfadiazine) cream, 1% is a topical antimicrobial drug indicated as an adjunct for the prevention and treatment of wound sepsis in patients with second and third degree burns. thermazene cream is contraindicated in patients who are hypersensitive to silver sulfadiazine or any of the other ingredients in the preparation. because sulfonamide therapy is known to increase the possibility of kernicterus, thermazene cream should not be used on pregnant women approaching or at term, on premature infants, or on newborn infants during the first 2 months of life.

Malta - English - Medicines Authority

wockhardt uk limited ash road north, wrexham, ll13 9uf, united kingdom - sulfadiazine - tablet - sulfadiazine 500 mg - antibacterials for systemic use

United States - English - NLM (National Library of Medicine)

wugan pharmaceutical (suzhou) co., ltd. - sulfadiazine (unii: 0n7609k889) (sulfadiazine - unii:0n7609k889) -

United States - English - NLM (National Library of Medicine)

aurora pharmaceutical, inc. - sulfadiazine (unii: 0n7609k889) (sulfadiazine - unii:0n7609k889), trimethoprim (unii: an164j8y0x) (trimethoprim - unii:an164j8y0x) - sulfadiazine 333 mg in 1 ml - equisul-sdt is contraindicated in horses with a known allergy to sulfadiazine, sulfonamide class antimicrobials, or trimethoprim.

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - silver sulfadiazine (unii: w46jy43ejr) (silver cation - unii:57n7b0k90a) - silver sulfadiazine 10 mg in 1 g -      silver sulfadiazine cream, usp 1% is a topical antimicrobial drug indicated as an adjunct for the prevention and treatment of wound sepsis in patients with second and third degree burns.      silver sulfadiazine cream, usp 1% is contraindicated in patients who are hypersensitive to silver sulfadiazine or any of the other ingredients in the preparation.      because sulfonamide therapy is known to increase the possibility of kernicterus, silver sulfadiazine cream, usp 1% should not be used on pregnant women approaching or at term, on premature infants, or on newborn infants during the first 2 months of life.      geriatric use. of the total number of subjects in clinical studies of silver sulfadiazine cream, usp 1% seven percent were 65 years of age and over. no overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater s

United States - English - NLM (National Library of Medicine)

h.j. harkins company, inc. - silver sulfadiazine (unii: w46jy43ejr) (silver sulfadiazine - unii:w46jy43ejr) - silver sulfadiazine 10 g in 1000 g - silver sulfadiazine cream is a topical antimicrobial drug indicated as an adjunct for the prevention and treatment of wound sepsis in patients with second and third degree burns. silver sulfadiazine cream is contraindicated in patients who are hypersensitive to silver sulfadiazine or any of the other ingredients in the preparation. because sulfonamide therapy is known to increase the possibility of kernicterus, silver sulfadiazine cream should not be used on pregnant women approaching or at term, on premature infants, or on newborn infants during the first 2 months of life.

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - silver sulfadiazine (unii: w46jy43ejr) (silver sulfadiazine - unii:w46jy43ejr) - silver sulfadiazine 10 mg in 1 g - silver sulfadiazine cream is a topical antimicrobial drug indicated as an adjunct for the prevention and treatment of wound sepsis in patients with second and third degree burns. silver sulfadiazine cream is contraindicated in patients who are hypersensitive to silver sulfadiazine or any of the other ingredients in the preparation. because sulfonamide therapy is known to increase the possibility of kernicterus, silver sulfadiazine cream should not be used on pregnant women approaching or at term, on premature infants, or on newborn infants during the first 2 months of life.